Affibody molecules: Potential for in vivo imaging of molecular targets for cancer therapy

Vladimir Tolmachev, Anna Orlova, Fredrik Y. Nilsson, Joachim Feldwisch, Anders Wennborg, Lars Abrahmsén

Research output: Contribution to journalReview articlepeer-review

107 Citations (Scopus)


Targeting radionuclide imaging of tumor-associated antigens may help to select patients who will benefit from a particular biological therapy. Affibody® molecules are a novel class of small (∼ 7 kDa) phage display-selected affinity proteins, based on the B-domain scaffold of staphylococcal protein A. A large library (3 × 109 variants) has enabled selection of high-affinity (up to 22 pM) binders for a variety of tumor-associated antigens. The small size of Affibody molecules provides rapid tumor localization and fast clearance from nonspecific compartments. Preclinical studies have demonstrated the potential of Affibody molecules for specific and high-contrast radionuclide imaging of HER2 in vivo, and pilot clinical data using indium-111 and gallium-68 labeled anti-HER2 Affibody tracer have confirmed its utility for radionuclide imaging in cancer patients.

Original languageEnglish
Pages (from-to)555-568
Number of pages14
JournalExpert Opinion on Biological Therapy
Issue number4
Publication statusPublished - Apr 2007
Externally publishedYes


  • Affibody molecules
  • HER2
  • Molecular imaging
  • Personalized medicine
  • Radionuclide targeting

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Affibody molecules: Potential for in vivo imaging of molecular targets for cancer therapy'. Together they form a unique fingerprint.

Cite this